Onchocerciasis: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
(3 intermediate revisions by one other user not shown)
Line 45: Line 45:
[[Onchocerciasis medical therapy|Medical Therapy]] | [[Onchocerciasis primary prevention|Primary Prevention]] | [[Onchocerciasis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Onchocerciasis future or investigational therapies|Future or Investigational Therapies]]
[[Onchocerciasis medical therapy|Medical Therapy]] | [[Onchocerciasis primary prevention|Primary Prevention]] | [[Onchocerciasis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Onchocerciasis future or investigational therapies|Future or Investigational Therapies]]
===Antimicrobial therapy===
===Antimicrobial therapy===
:* '''Cutaneous filariasis - Onchocercia volvulus, Loa loa'''<ref name="pmid20739055">{{cite journal| author=Taylor MJ, Hoerauf A, Bockarie M| title=Lymphatic filariasis and onchocerciasis. | journal=Lancet | year= 2010 | volume= 376 | issue= 9747 | pages= 1175-85 | pmid=20739055 | doi=10.1016/S0140-6736(10)60586-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20739055  }} </ref><ref name="pmid22632644">{{cite journal| author=Knopp S, Steinmann P, Hatz C, Keiser J, Utzinger J| title=Nematode infections: filariases. | journal=Infect Dis Clin North Am | year= 2012 | volume= 26 | issue= 2 | pages= 359-81 | pmid=22632644 | doi=10.1016/j.idc.2012.02.005 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22632644  }} </ref>
::* Preferred regimen (1): [[Doxycycline]] 150 μg/kg single dose
::* Preferred regimen (2): ([[Doxycycline]] 100 mg PO qd for 6 weeks {{or}} 200 mg PO qd for 4 weeks) {{then}} [[Ivermectin]] after 4-6 months 150 μg/kg single dose
::* Preferred regimen (3): [[Doxycycline]] 200 mg PO qd for 6 weeks {{then}} [[Ivermectin]] after 4-6 months 150 μg/kg single dose




Line 60: Line 64:
[[Category:Neglected diseases]]
[[Category:Neglected diseases]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 


[[de:Onchozerkose]]
[[de:Onchozerkose]]
Line 72: Line 76:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WS}}
{{WS}}
==References==
{{reflist|2}}

Latest revision as of 18:31, 18 September 2017

Onchocerca volvulus
O. volvulus, the causative agent of river blindness.
O. volvulus, the causative agent of river blindness.
Scientific classification
Kingdom: Animalia
Phylum: Nematoda
Class: Secernentea
Order: Spirurida
Family: Filariidae
Genus: Onchocerca
Species: O. volvulus
Binomial name
Onchocerca volvulus
Bickel 1982

Onchocerciasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Onchocerciasis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Onchocerciasis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Onchocerciasis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Onchocerciasis

CDC on Onchocerciasis

Onchocerciasis in the news

Blogs on Onchocerciasis

Directions to Hospitals Treating Onchocerciasis

Risk calculators and risk factors for Onchocerciasis

For patient information, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Kalsang Dolma, M.B.B.S.[2]

Synonyms and keywords: Onchocercosis; river blindness; Robles disease; onchocerca volvulus infection

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Onchocerciasis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Primary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Antimicrobial therapy

  • Cutaneous filariasis - Onchocercia volvulus, Loa loa[1][2]
  • Preferred regimen (1): Doxycycline 150 μg/kg single dose
  • Preferred regimen (2): (Doxycycline 100 mg PO qd for 6 weeks OR 200 mg PO qd for 4 weeks) THEN Ivermectin after 4-6 months 150 μg/kg single dose
  • Preferred regimen (3): Doxycycline 200 mg PO qd for 6 weeks THEN Ivermectin after 4-6 months 150 μg/kg single dose


Case Studies

Case #1

External Links


Template:Helminthiases


de:Onchozerkose it:Oncocercosi fi:Jokisokeus


Template:WS

References

  1. Taylor MJ, Hoerauf A, Bockarie M (2010). "Lymphatic filariasis and onchocerciasis". Lancet. 376 (9747): 1175–85. doi:10.1016/S0140-6736(10)60586-7. PMID 20739055.
  2. Knopp S, Steinmann P, Hatz C, Keiser J, Utzinger J (2012). "Nematode infections: filariases". Infect Dis Clin North Am. 26 (2): 359–81. doi:10.1016/j.idc.2012.02.005. PMID 22632644.